Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy

Alyssa M. Burgart*, David Magnus, Holly K. Tabor, Erin Daksha Talati Paquette, Joel Frader, Jaqueline J. Glover, Brian M. Jackson, Charlotte H. Harrison, David K. Urion, Robert J. Graham, John F. Brandsema, Chris Feudtner

*Corresponding author for this work

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

The US Food and Drug Administration’s December 2016 approval of nusinersen for the treatment of patients with all subtypes of spinal muscular atrophy ushered in a new era for patients with spinal muscular atrophy, their families, and all those involved in their care. The extreme cost of the medication and the complicated logistical requirements for administering nusinersen via lumbar puncture have created practical challenges that raise important ethical considerations. We discuss 6 challenges faced at the institutional level in the United States: cost, limited evidence, informed consent, treatment allocation, fair distribution of responsibilities, and transparency with stakeholders. These challenges must be understood to ensure that patients with spinal muscular atrophy benefit from treatment, are protected from harm, and are treated fairly.

Original languageEnglish (US)
Pages (from-to)188-192
Number of pages5
JournalJAMA Pediatrics
Volume172
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Spinal Muscular Atrophy
Costs and Cost Analysis
Spinal Puncture
United States Food and Drug Administration
Informed Consent
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Burgart, Alyssa M. ; Magnus, David ; Tabor, Holly K. ; Paquette, Erin Daksha Talati ; Frader, Joel ; Glover, Jaqueline J. ; Jackson, Brian M. ; Harrison, Charlotte H. ; Urion, David K. ; Graham, Robert J. ; Brandsema, John F. ; Feudtner, Chris. / Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy. In: JAMA Pediatrics. 2018 ; Vol. 172, No. 2. pp. 188-192.
@article{6808d118574741dbbcd784ae38e90f2b,
title = "Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy",
abstract = "The US Food and Drug Administration’s December 2016 approval of nusinersen for the treatment of patients with all subtypes of spinal muscular atrophy ushered in a new era for patients with spinal muscular atrophy, their families, and all those involved in their care. The extreme cost of the medication and the complicated logistical requirements for administering nusinersen via lumbar puncture have created practical challenges that raise important ethical considerations. We discuss 6 challenges faced at the institutional level in the United States: cost, limited evidence, informed consent, treatment allocation, fair distribution of responsibilities, and transparency with stakeholders. These challenges must be understood to ensure that patients with spinal muscular atrophy benefit from treatment, are protected from harm, and are treated fairly.",
author = "Burgart, {Alyssa M.} and David Magnus and Tabor, {Holly K.} and Paquette, {Erin Daksha Talati} and Joel Frader and Glover, {Jaqueline J.} and Jackson, {Brian M.} and Harrison, {Charlotte H.} and Urion, {David K.} and Graham, {Robert J.} and Brandsema, {John F.} and Chris Feudtner",
year = "2018",
month = "2",
day = "1",
doi = "10.1001/jamapediatrics.2017.4409",
language = "English (US)",
volume = "172",
pages = "188--192",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "2",

}

Burgart, AM, Magnus, D, Tabor, HK, Paquette, EDT, Frader, J, Glover, JJ, Jackson, BM, Harrison, CH, Urion, DK, Graham, RJ, Brandsema, JF & Feudtner, C 2018, 'Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy', JAMA Pediatrics, vol. 172, no. 2, pp. 188-192. https://doi.org/10.1001/jamapediatrics.2017.4409

Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy. / Burgart, Alyssa M.; Magnus, David; Tabor, Holly K.; Paquette, Erin Daksha Talati; Frader, Joel; Glover, Jaqueline J.; Jackson, Brian M.; Harrison, Charlotte H.; Urion, David K.; Graham, Robert J.; Brandsema, John F.; Feudtner, Chris.

In: JAMA Pediatrics, Vol. 172, No. 2, 01.02.2018, p. 188-192.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy

AU - Burgart, Alyssa M.

AU - Magnus, David

AU - Tabor, Holly K.

AU - Paquette, Erin Daksha Talati

AU - Frader, Joel

AU - Glover, Jaqueline J.

AU - Jackson, Brian M.

AU - Harrison, Charlotte H.

AU - Urion, David K.

AU - Graham, Robert J.

AU - Brandsema, John F.

AU - Feudtner, Chris

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The US Food and Drug Administration’s December 2016 approval of nusinersen for the treatment of patients with all subtypes of spinal muscular atrophy ushered in a new era for patients with spinal muscular atrophy, their families, and all those involved in their care. The extreme cost of the medication and the complicated logistical requirements for administering nusinersen via lumbar puncture have created practical challenges that raise important ethical considerations. We discuss 6 challenges faced at the institutional level in the United States: cost, limited evidence, informed consent, treatment allocation, fair distribution of responsibilities, and transparency with stakeholders. These challenges must be understood to ensure that patients with spinal muscular atrophy benefit from treatment, are protected from harm, and are treated fairly.

AB - The US Food and Drug Administration’s December 2016 approval of nusinersen for the treatment of patients with all subtypes of spinal muscular atrophy ushered in a new era for patients with spinal muscular atrophy, their families, and all those involved in their care. The extreme cost of the medication and the complicated logistical requirements for administering nusinersen via lumbar puncture have created practical challenges that raise important ethical considerations. We discuss 6 challenges faced at the institutional level in the United States: cost, limited evidence, informed consent, treatment allocation, fair distribution of responsibilities, and transparency with stakeholders. These challenges must be understood to ensure that patients with spinal muscular atrophy benefit from treatment, are protected from harm, and are treated fairly.

UR - http://www.scopus.com/inward/record.url?scp=85041689070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041689070&partnerID=8YFLogxK

U2 - 10.1001/jamapediatrics.2017.4409

DO - 10.1001/jamapediatrics.2017.4409

M3 - Review article

C2 - 29228163

VL - 172

SP - 188

EP - 192

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 2

ER -